ANN ARBOR, Mich., Oct. 31, 2014 /PRNewswire/ -- Lycera Corp., a biopharmaceutical company developing breakthrough oral immune modulators to treat autoimmune disease and cancer, today announced that data on the anti-tumor activity of novel synthetic RORgamma agonist product candidates will be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC) being held November 6-9, 2014 at the Gaylord National Hotel & Convention Center, National Harbor, MD.  The poster, entitled "Novel synthetic RORgamma agonist compounds as a potential anti-tumor therapeutic approach", will be presented beginning Friday, November 7.  This poster also was selected by SITC to be highlighted in an oral presentation on November 8.

About Lycera

Lycera is a privately held biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer. Our approach builds on an in-depth understanding of the orchestration of immune response in disease progression.

Lycera product development programs are enhanced by our established global relationships with many leading chemists, scientists, biologists and clinical researchers. We are currently advancing novel small molecule compounds from distinct, yet complementary, areas of research, including immune metabolism, cell signaling and immune cell differentiation. In addition to a robust proprietary pipeline, the company has an established research collaboration with Merck to discover, develop and commercialize small-molecule therapies for autoimmune disorders.

Contact:
Bill Berry
Berry & Company Public Relations
bberry@berrypr.com
212 253 8881

SOURCE Lycera Corp.